3 min read
The complexity of global drug development continues to increase as pharmaceutical companies conduct multi-regional clinical trials, pursue simultaneous market authorizations, and navigate evolving Regulatory requirements across multiple jurisdictions. According to industry estimates, more than 50% of clinical development programs today involve multiple countries, requiring organizations to manage increasingly complex safety, efficacy, and labeling information throughout the product lifecycle. As development programs expand globally, maintaining consistency across product information becomes critical to Regulatory compliance and successful commercialization.
One of the most effective ways to establish this consistency is to develop a robust Company Core Data Sheet (CCDS). For investigational products, a well-structured CCDS serves as the foundation for global labeling governance, helping organizations align safety information, support Regulatory submissions, and prepare for future commercialization activities.
What is a CCDS?
The Company Core Data Sheet is a company-maintained document that contains the core information considered essential by the marketing authorization holder regarding a medicinal product. It typically includes:
- Core safety information
- Indications and usage
- Dosage and administration
- Clinical pharmacology information
- Pharmacokinetics information
- Pre-clinical safety data
- Pharmaceutical particulars
Although often associated with marketed products, establishing a CCDS during clinical development can provide significant strategic advantages.
Why CCDS Development Should Begin Early
Many organizations wait until late-stage development or pre-launch activities to establish a CCDS. However, early development of a global core labeling document helps create consistency as clinical data evolves.
Benefits include:
Improved Global Alignment
A CCDS provides a centralized reference point for product information, reducing inconsistencies across regions and study programs.
Enhanced Regulatory Efficiency
Regulatory teams can leverage a common source document when preparing submissions for different health authorities.
Better Safety Governance
As new clinical and safety data emerge, updates can be managed consistently across development programs and regions.
Reduced Lifecycle Complexity
Organizations that establish labeling governance early often experience smoother transitions from development to commercialization.
Challenges in Developing CCDS for Investigational Products
Creating a CCDS during clinical development is not simply challenging. A few of them are listed below:
Evolving Clinical Data
Investigational products undergo continuous evaluation, meaning product information may change frequently throughout development.
Regional Regulatory Differences
Health authorities may have differing expectations regarding product information, safety language, and clinical claims.
Cross-Functional Coordination
Successful CCDS development requires collaboration among Regulatory Affairs, Clinical Development, Medical Affairs, Safety, Biostatistics, Commercial, Marketing, Quality, etc.
Emerging Safety Information
New risks and safety findings must be incorporated while maintaining consistency across all related documentation.
Without a structured governance process, these challenges can lead to discrepancies and increased compliance risk.
Best Practices for CCDS Development
Establish Global Labeling Governance Early
Organizations should define clear ownership and decision-making processes for CCDS management.
Use a Risk-Based Review Framework
Safety information and clinical updates should be assessed systematically to determine their impact on global product information.
Align CCDS with Development Milestones
The CCDS should evolve alongside key clinical and Regulatory milestones to ensure relevance and accuracy.
Maintain Robust Change Control
Every update should be documented, reviewed, and communicated through established governance processes.
Integrate Regulatory Intelligence
Monitoring global Regulatory trends helps organizations anticipate future labeling requirements and reduce approval delays.
The Role of CCDS in Global Labeling Strategy
A well-developed CCDS serves as the cornerstone of a global labeling strategy. It provides the framework for developing:
- Regional prescribing information
- Patient leaflets
- Local product labels (Artworks)
- Future electronic product information (ePI)
This centralized approach helps organizations maintain consistency while accommodating market-specific requirements.
Current Industry Trends
In 2026, pharmaceutical companies are increasingly adopting structured content management, digital labeling platforms, and global governance models to improve labeling efficiency. At the same time, regulators continue emphasizing consistency between clinical data, safety information, and approved product labeling.
Organizations are also recognizing the importance of preparing labeling frameworks earlier in development to support accelerated approvals, global launches, and lifecycle management activities.
As digital labeling initiatives expand worldwide, CCDS documents are becoming even more important as authoritative sources for structured content and future electronic labeling requirements.
Conclusion
Developing a CCDS for investigational products is a strategic investment in future labeling success. By establishing a robust global core document early in development, organizations can improve consistency, strengthen Regulatory compliance, streamline submissions, and support efficient lifecycle management.
A well-governed CCDS enables pharmaceutical companies to move from fragmented labeling practices toward a coordinated global strategy that supports both development and commercialization objectives.
Freyr Solutions helps pharmaceutical companies develop and maintain CCDS documents, establish global labeling governance frameworks, manage lifecycle labeling activities, and align product information across global markets. Partner with Freyr to build a scalable labeling foundation that supports successful development and commercialization.
